Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Stéphanie Truant

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2828-4864; OpenAlex author ID A5066576409. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: 5 papers

Papers 17

  1. Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study. Co-author DOI 10.1016/j.esmogo.2025.100144↗
  2. Nationwide analysis of one-year mortality following pancreatectomy in 17,183 patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2024.10.011↗
  3. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  4. Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter T… Co-author DOI 10.1245/s10434-024-16735-2↗
  5. Influence of pre-operative sarcopenia on post-operative hepatic steatosis after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/jgo-24-700↗
  6. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  7. Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study. Co-author DOI 10.1186/s12957-024-03393-7↗
  8. Impact on survival of sarcopenia, systemic inflammatory response and anthropometric factors after pancreatectomy for resectable pancreatic adenocarcinoma. Co-author DOI 10.1186/s12957-024-03510-6↗
  9. Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre observational cohort study (CAPANCOGEN). Co-author DOI 10.1016/j.pan.2023.06.010↗
  10. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective obs… Co-author DOI 10.1016/j.ejca.2022.01.040↗
  11. A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms. Co-author DOI 10.1111/boc.202100003↗
  12. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Co-author DOI 10.1053/j.gastro.2019.12.009↗
  13. A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Co-author DOI 10.3390/cancers12040783↗
  14. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype. Last author DOI 10.1002/mc.23090↗
  15. A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. Co-author DOI 10.1186/s12885-018-4906-4↗
  16. Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine. First author DOI 10.21873/invivo.11122↗
  17. Deep Vein Thrombosis: An Independent Poor Prognosis Factor of Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.21873/anticanres.11135↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mehdi El Amrani · 7 shared papers, 2019–2025 · strength 1.29
  2. Anthony Turpin · 4 shared papers, 2016–2024 · strength 0.56
  3. Kaja Balcer · 2 shared papers, 2024–2025 · strength 0.48
  4. Ugo Marchèse · 2 shared papers, 2025 · strength 0.39
  5. Jonathan Garnier · 2 shared papers, 2024–2025 · strength 0.39
  6. Charles Poiraud · 2 shared papers, 2022–2024 · strength 0.34
  7. Mathias Brügel · 2 shared papers, 2022–2023 · strength 0.27
  8. Camille Evrard · 2 shared papers, 2022–2023 · strength 0.27
  9. Nicolas Williet · 2 shared papers, 2022–2023 · strength 0.27
  10. David Tougeron · 2 shared papers, 2022–2023 · strength 0.27
  11. Olivier Bouché · 2 shared papers, 2022–2023 · strength 0.27
  12. Alexandre Doussot · 2 shared papers, 2022–2025 · strength 0.26
  13. Louis Caputo · 1 shared paper, 2025 · strength 0.26
  14. Laurent Boyer · 1 shared paper, 2025 · strength 0.23
  15. Olivıer Turrini · 1 shared paper, 2024 · strength 0.23
  16. Audrey Vincent · 2 shared papers, 2019–2022 · strength 0.20
  17. Isabelle VAN SEUNINGEN · 2 shared papers, 2019–2022 · strength 0.20
  18. Marine Perrier · 1 shared paper, 2023 · strength 0.16
  19. Bertrand Napoléon · 2 shared papers, 2018–2020 · strength 0.16
  20. Eric Assénat · 2 shared papers, 2018–2020 · strength 0.16
  21. Cindy Canivet · 2 shared papers, 2018–2020 · strength 0.16
  22. Louis Buscail · 2 shared papers, 2018–2020 · strength 0.16
  23. Barbara Bournet · 2 shared papers, 2018–2020 · strength 0.16
  24. Lilian Schwartz · 1 shared paper, 2025 · strength 0.16
  25. Julie Navez · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.